Home » News » CROs/Service Providers » Algorithme Gets 240 Bed Phase I Unit from BASi

Algorithme Gets 240 Bed Phase I Unit from BASi

Thursday, July 10, 2008

Bioanalytical Systems (BASi) sold its Baltimore-based clinical pharmacology research unit to Montreal, Canada-based phase I/bioequivalence CRO Algorithme. BASi sold the 68,000-square-foot, 240-bed unit for $850,000 in cash. Since it is BASi’s only early phase research facility, BASi is exiting the phase I first-in-human clinical trials market. The company is primarily a preclinical, bioanalytical and immuno-assay services firm. It also manufactures specialized equipment for liquid chromatography, in vivo sampling, veterinary medicine and electrochemistry.

According to Algorithme, the 10-year-old company is the largest privately held Québec-owned organization specializing in research services for the pharmaceutical industry. With 400 employees, it maintains four offices in Montreal, including main headquarters and laboratory, a 16,000-square-foot, 80-bed clinic, a medical screening center and now the new BASi unit. The company stated it conducts more than 200 studies per year and reported sales of over $32 million in 2005.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!